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Abstract:  
Problem: System-wide improvement of chronic disease care is challenging because it 
requires collaboration and communication across organisational and professional boundaries. 
Managed clinical networks are one potential solution, but there is little evidence of their 
effectiveness. 
Design and setting: Retrospective, mixed-methods evaluation of the form and impact of 
quality improvement in the Tayside Diabetes Managed Clinical Network (MCN) 1998-2005. 
Strategies for change: Progressive implementation of multiple quality improvement 
strategies predominately directed at individuals and clinical teams (guideline development 
and dissemination; education; clinical audit; encouragement of multidisciplinary team 
working; task redesign). Information technology played an important role in supporting QI 
activity, but participants identified it as facilitative rather than delivering QI by itself. More 
important was achieving widespread clinical engagement through persuasion and appeal to 
shared professional values by clinical leaders.  
Effects of change: Simple process measures such as glycated haemoglobin measurement 
rapidly improved. More complex process measures such as eye screening improved more 
slowly, and were more dependent on redesign of the care pathway. Improvement was greater 
for type-2 than type-1 diabetes. Significant shifts of care for type-2 diabetes into primary care 
were achieved, but were harder to achieve without additional resources. 
Lessons learnt: Delivering better care to whole populations across organisational and 
professional boundaries required sustained work over long periods, and at all levels of the 
system of care. Past network focus on clinical collaboration has been effective at improving 
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clinical process and outcome, and the network is now prioritising work with managers and 
patients to support future redesign. 
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Key learning points 
Quality improvement (QI) activity within the Tayside Diabetes Managed Clinical Network 
(TDMCN) initially focused on changing individual and small team professional practice, and 
task redesign within the existing care pathway. This delivered large improvements in 
processes of care, and to a lesser extent, intermediate outcomes.  
 
Information technology played an important role in QI activity by supporting clinical care 
and communication (via a web-based shared record), by automating audit and feedback (via 
the regional registry) and by facilitating knowledge dissemination and management (via the 
network website).  
 
Key to network success was engagement of primary care and specialist clinicians in quality 
improvement. This was achieved through negotiation to achieve consensus across the 
multidisciplinary team on network vision and short to medium term goals, facilitated by 
leadership being enthusiastic and committed, and shared between specialists and general 
practitioners. 
 
Participants in the evaluation identified lack of patient and managerial involvement during 
the network’s formative years as problematic. In the last 2-3 years, the network has actively 
sought to increase patients’ involvement in network planning and self-care, and to make 
general NHS management more engaged partners in network quality improvement.   
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BACKGROUND 
Outline of problem 
The rising incidence and prevalence of diabetes presents a growing challenge to health 
services internationally.1 Systematically implementing national diabetes guidelines2 is 
difficult though, because it requires clinical care and quality improvement to be co-ordinated 
across existing health service and disciplinary boundaries. In the UK, National Service 
Frameworks provide additional guidance on how clinical guidelines can be delivered, and 
recommend the creation of clinical networks with responsibility for all diabetes care in an 
area.3-7  However, there is little reported evidence as to how networks should be organised or 
their effectiveness.8 9 This paper describes the form and impact of quality improvement work 
in the Tayside Diabetes Managed Clinical Network (TDMCN), which has previously been 
identified as a model for UK diabetes services.10  
 
Outline of the context 
The Tayside Region of Scotland has a population of ~385,000, and includes deprived urban 
areas, small towns, and remote, rural areas. Primary healthcare is provided by 72 general 
practices, with specialist diabetes services delivered from three sites (a teaching hospital 
diabetes centre, and two district general hospitals), plus outreach clinics in small towns 
distant from these. The number of people with diabetes in the region increased by ~50% 
between January 1998 and January 2005, from 8,846 (2.3% prevalence) to 13,527 (3.5%).  
 
This report is based on an independent evaluation of TDMCN conducted in 2004/5. The 
evaluation examined the quality improvement (QI) strategies used by the network between 
1998 and 2005 through analysis of network documents (annual reports, planning documents, 
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minutes of network meetings), observation of meetings, and qualitative interview with 
multidisciplinary team members and patients. The impact of these activities was 
quantitatively examined by analysis of data extracted from the regional diabetes register. The 
evaluation was approved by Tayside Local Research Ethics Committee. 
This report is based on an independent evaluation of TDMCN conducted in 2004/5. The 
evaluation examined the quality improvement (QI) strategies used by the network between 
1998 and 2005 through analysis of network documents (annual reports, planning documents, 
minutes of network meetings), observation of meetings, and qualitative interview with 
multidisciplinary team members and patients. The impact of these activities was 
quantitatively examined by analysis of data extracted from the regional diabetes register. The 
evaluation was approved by Tayside Local Research Ethics Committee. 
 
 
 
Professionals were purposively sampled from MCN committees, and from general practices 
that were high and low users of the MCN website. We were unable to identify high and low 
website users reliably in hospital settings and so used snowballing techniques to recruit 
hospital professionals with variable levels of commitment to the MCN. People with diabetes 
were sampled from high and low web-using general practices, but initial analysis indicated 
that they had little knowledge of the MCN as an organisation. We therefore instead recruited 
lay representatives on MCN committees to explore the perspectives of informed patients 
(Table 2). Semi-structured interview schedules were used and lasted 30-70 minutes, and were 
taped and transcribed.  
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Table 1: In-depth interviews 
Interviews with: Initial sampling frame Completed 
MCN core management group and Tayside 
Diabetes Advisory Group (TDAG) 
6 9 
General practitioners 4 3 
Practice nurses 4 4 
Practice managers 4 A 
Hospital professionals 6 8 
Patients sampled via practices 8 4 
Supplementary interviews (patient 
representatives and Trust managers) 
As indicated by initial 
analysis 
5 
Total 32 36 
 
 
ASSESSMENT OF PROBLEMS 
Since the late 1990s, clinical data for all people with diabetes in Tayside has been entered 
into a regional register. Accuracy and completeness is maintained by the use of a unique 
identifier throughout NHS Tayside (the Community Health Index number), and routine data 
checking and correction by MCN data facilitators. In 1998, a complete audit of all people 
with diabetes in Tayside identified widespread deficiencies in care, with inappropriately low 
levels of clinical process and outcome (table 1). This prompted widespread recognition that 
change was essential in both primary and secondary care.11 12  
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Table 1: Quality of diabetes care in Tayside 1/1/98 
Indicator* Type-1 diabetes  
% achieving indicator 
(numerator/denominator) 
Type-2 diabetes 
% achieving indicator 
(numerator/denominator) 
Glycated haemoglobin measured  58.2 (686/1178)  58.8 (4511/7668) 
Blood pressure measured  50.8 (598/1178)  61.1 (4685/7668) 
Total cholesterol measured   20.0 (236/1178)  26.5 (2031/7668) 
Creatinine measured  31.4 (370/1178)  41.7 (3199/7668) 
Foot vascular status assessed  35.5 (418/1178)  47.2 (3621/7668) 
Foot neurological status assessed  28.5 (336/1178)  38.2 (2929/7668) 
Retinal screening  57.3 (675/1178)  66.6 (5111/7668) 
Smoking status recorded  77.6 (914/1178)  82.9 (6357/7668) 
Glycated haemoglobin ≤10%   77.7 (533/686)  90.4 (4077/4511) 
Glycated haemoglobin ≤7%  13.6 (93/686)  42.8 (1933/4511) 
Systolic blood pressure  ≤ 140mmHg  78.4 (469/598)  50.7 (2374/4685) 
Diastolic blood pressure ≤ 80mmHg  75.4 (451/598)  57.8 (2710/4685) 
Total cholesterol ≤ 5mmol/l  43.2 (103/236)  30.7 (624/2031) 
 
*Process measures = percentage of patients with record of process in previous 12 months; intermediate outcome 
measures = percentage of patients with measurement in last 12 months achieving target 
 
 
STRATEGIES FOR CHANGE 
Quality improvement activities implemented 
The working assumption from the outset was that there are no single interventions, or ‘magic 
bullets’, that are guaranteed to improve quality.13 TDMCN therefore progressively 
implemented a range of complementary QI strategies, within a supportive national context 
that included national guidelines14 and guidance,4 and quality improvement orientated 
regulation15 by NHS Quality Improvement Scotland16. Table 2 shows the scope of the QI 
activities undertaken by TCMCN, and when each was first implemented. Analysis drew on 
Ferlie and Shortell’s multilevel framework for healthcare quality improvement17 to which 
network activities to reinforce shared goals and systematic care broadly map, although 
TDMCN predates and did not explicitly follow this, or any other QI model.  
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Table 2: Quality improvement strategies used in Tayside Diabetes Managed Clinical Network, and in Scotland 
 
Levels17 
Strategies used by TDMCN 
(Strategies not used by TDMCN in brackets) 
Examples (identified from documentary and interview data) Used from 
when? 
Individual professional 
Education 
Data feedback 
Benchmarking 
Guidelines, protocol, pathway implementation 
Leadership development 
 
(Academic detailing) 
 
Single and multi-professional, varying levels, locally organised and/or using wider resources eg Warwick Diabetes Course18 
Routine via stand-alone regional register initially, then via DARTS/SCI-DC19 
Routine individual practice comparison with regional and locality averages via DARTS/SCI-DC19 
Tayside Diabetes Handbook available via MCN website is a locally modified set of national guidelines (SIGN)14 19  
Strong central leadership with considerable delegation to task focused TDAG subgroups19 
 
(Not explicitly used) 
 
1998 
1996 
1998 
2000 
1999 
 
Groups/teams of professionals 
Team development  
Task redesign  
Clinical audits 
Guidelines, protocol, pathway implementation 
 
 
(Breakthrough collaborative) 
 
Multi-disciplinary collaborative working central to MCN ethos18 
For example, of eye screening, education for people with newly diagnosed type-2 diabetes, care for patients starting insulin18 
Stand-alone regional register was designed for audit; DARTS/SCI-DC includes practice audit tools19 
Single shared guidelines and protocols for all professional groups disseminated via MCN website.19 
Care pathway redesign in 2002, but implementation has been slow 
 
(Some Tayside practices are part of the Scottish Care Collaborative which has a diabetes arm, but not an MCN initiative) 
 
1998 
2000 
1996 
2000 
2002 
 
(2003) 
Organisation 
Quality assurance 
Organisation development 
Knowledge management /transfer 
 
Public disclosure 
 
(Continuous quality improvement) 
 
Routine data collection and audit via DARTS/SCI-DC, locally agreed but consistent with national standards14 
Regional service redesign with creation of new care pathway, although never fully implemented20 
Regionally co-ordinated multidisciplinary education and training, knowledge dissemination via MCN website and 
newsletters19 
Annual reports, regional quality data and key network documents published via MCN website19 
 
(Not explicitly used) 
 
1996 
2002 
2000 
 
2000 
 
Larger system / environment 
National bodies 
 
Accrediting licensing agencies 
Payment policies 
 
(Evidence-based practice centres) 
(Legal system) 
 
Scottish Intercollegiate Guidelines Network guidelines for diabetes14;  
Scottish Diabetes Group and Framework4 21 
Quality Improvement Scotland review of diabetes services against national standards, and MCN accreditation16 
2004 General Medical Services (General Practitioner) contract22 
 
 
1996 
2002 
2002 
2004 
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Between 1998 and 2005, TDMCN primarily encouraged systematic, guideline-driven care by 
focusing on changing the clinical practice of individual professionals and small, 
multidisciplinary teams. Areas of activity identified by participants as key are briefly 
described below (more detailed information can be found on the network website19). 
 
a) Guidelines, protocol, pathway implementation 
National guidelines were locally modified to create the Tayside Diabetes Handbook, 
available in both paper and electronic form. Matching patient information leaflets were 
created and made available electronically, combining information about both diabetes and 
services available. Guideline implementation was achieved primarily through audit, feedback, 
and professional education, focusing on changing routine clinical practice, supplemented 
where necessary with task redesign. Between 1998 and 2002, the emphasis was on ensuring 
that key care processes and outcomes were delivered, with less attention paid to ensuring that 
only patients needing specialist care attended hospital. In 2002, a new care pathway was 
defined by a multi-disciplinary working group, which clearly identified when primary or 
specialist care was appropriate for people with type-2 diabetes.20 Implementation was 
monitored through changes in the proportion of people with type-2 diabetes attending 
hospital.  
 
b) Education 
Professional education has been tailored to varying levels of clinician interest, from locality-
based multi-disciplinary diabetes forums where educational form and content were 
determined by participants, through development of a local MSc level module, to sponsorship 
for professionals to undertake an intensive course in diabetes management.23 
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c) Audit, feedback and benchmarking 
Routine feedback to practices of performance on clinical process and outcome measures has 
occurred since 1996 using the regional register to provide comparison with other practices in 
the locality. Since 2000, network performance has been publicly reported annually.  
  
d) Task redesign within the existing care pathway 
Examples include rapid delivery of national policy requirements for universal digital 
retinopathy screening in 2003/4 including extending the use of mobile screening units to 
ensure equity of access in rural areas; design and implementation of group education for 
people with newly diagnosed type-2 diabetes; and group rather than individual conversion to 
insulin therapy. 
 
e) Care pathway redesign 
From the outset, the majority of patients with type-2 diabetes received the bulk of their care 
in the community, either exclusively or as part of a ‘shared-care’ scheme. However, large 
numbers of uncomplicated patients attending hospital clinics with limited capacity led to 
significant waits for routine appointments.  In 2002, the network therefore created a new care 
pathway20 to focus specialist resources on those most likely to benefit from them, with full 
implementation dependent on significantly increasing the proportion of people with type-2 
diabetes cared for exclusively in primary care. In the absence of new resources, guidelines 
and persuasion were the only strategies available to achieve this.  
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Network resources and organisation facilitating change 
a) Resources 
Since 1998, there has been no change in specialist medical, dietetics or podiatry resource, 
apart from the addition of one whole time equivalent diabetes specialist nurse, and investment 
in staff and equipment for retinal screening from 2003. Formalisation as an MCN led to 
stable funding for a whole-time network manager, secretary and data facilitator, and part-time 
clinical lead and IT support posts. However, considerable time was voluntarily given to MCN 
development by its clinical members, and diabetes-focused work in primary care was not 
formally reimbursed until the introduction of a new contract in 2004. Changes in care 
therefore primarily reflect a widespread clinical commitment to implement systematic care, 
rather than direct investment in service delivery.  
 
b) Network organisation and leadership  
From the outset, leadership in TDMCN has been shared, with key posts held jointly by a 
specialist and a primary care doctor. Overall responsibility for quality improvement and 
setting MCN strategy lies with the Tayside Diabetes Advisory Group, which has 
representation from patients, all professional groups involved in diabetes services, and NHS 
Tayside Health Board. Responsibility for specific developments has been delegated to 
clinically-led sub-groups focused on particular tasks (including guidelines development; eye, 
foot  and pregnancy care; data governance; and professional and patient education).19 
Clinicians interviewed for the evaluation identified this combination of shared leadership and 
involvement of all professional groups in network planning as key to ensuring widespread 
clinical commitment to change, with trust engendered by shared professional values and 
explicit negotiation of priorities and activities.  
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c) Information technology 
IT has been at the heart of QI activity since network inception. The original standalone, 
manually updated regional register of the late 1990s evolved into a web-based diabetes record 
from 2000 that is automatically populated from primary care and hospital IT systems, and has 
since been implemented across Scotland. The record supports individual clinical care, audit 
and feedback to practices, and monitoring of process and outcome across the network. It 
additionally underpins network-organised care including recall for eye-screening and booking 
of group education for people with newly diagnosed type-2 diabetes. Access to the clinical 
record along with audit and data feedback tools is via the MCN website, which also provides 
access to the Tayside Diabetes Handbook, patient information leaflets, and information about 
the network including personnel, services provided, and network reports and strategy 
documents.19  
 
Effects of change 
a) Clinical process and outcome 
Tables 3 and 4 compare clinical processes and outcomes in January 1998 and January 2005 
for type-1 and type-2 diabetes. Figures 1-8 in the web-supplement show patterns of change 
over the whole period. Reflecting implementation of routine registration and recall, simple 
clinical processes performed by individual clinicians (taking blood, measuring blood 
pressure, recording smoking status) rapidly improved early in network development, reaching 
high levels by 2000 with slow improvement towards maximum since. More complex 
processes like foot examination have shown continued slow improvement over the whole 
period, and retinal screening has only shown significant improvement since the redesign of 
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the regional eye screening service (although the quality of both foot and eye screening has 
improved over the whole period with shifts to routine use of monofilaments for foot 
examination, and to all retinal screening now being by quality-assured digital photography). 
Process measures for people with type-2 diabetes have improved more than for those with 
type-1.  
 
Interpretation of intermediate outcome data should be cautious, since significant numbers of 
patients were not regularly screened in the early years. Since unscreened patients are likely to 
have worse control, engaging more patients in care may initially lead to worse measured 
outcomes.24 For people with type-2 diabetes, mean systolic and diastolic blood pressure and 
cholesterol are significantly lower. Glycaemic control worsened in the first three years but 
has shown improvement since. For people with type-1 diabetes, intermediate outcomes are 
only improved for cholesterol control (although again, glycaemic control worsened in the 
early years of the network, and has been improving since).  
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Table 3: Change in quality 1st January 1998 to 1st January 2005 for people with type-1 diabetes 
Indicator* % (n) achieving 
measure 1/1/98  
% (n) achieving 
measure 1/1/05  
Difference 1998-2005 
(95% confidence interval) 
p-value# Pattern of change (see web-only 
figures 1-8) 
Glycated haemoglobin measured 58.2  (1178) 91.2  (1471)  33.0  (29.8 to 36.2) <0.001 Rapid rise before 2000 
Blood pressure measured 50.8  (1178) 77.3  (1471)  26.5  23.0 to 30.1) <0.001 Rapid rise before 2000 
Cholesterol measured 20.0  (1178) 71.0  (1471)  51.0  (47.8 to 54.3) <0.001 Rapid rise before 2000 
Creatinine measured 31.4  (1178) 79.1  (1471)  47.7  (44.3 to 51.0) <0.001 Rapid rise before 2000 
Smoking recorded 77.6  (1178) 93.5  (1471)  15.9  (13.2 to 18.6) <0.001 Rapid rise before 2000 
Foot vascular status assessed 35.5  (1178)  61.7  (1471)  26.2  (22.5 to 29.9) <0.001 Slow continuous improvement 
Foot neurological status assessed 28.5  (1178) 60.8  (1471)  32.3  (28.7 to 35.9) <0.001 Slow continuous improvement 
Retinal screening 57.3  (1178) 74.2  (1471)  16.9  (13.1 to 20.5) <0.001 Improvement after redesign in 2003 
Glycated haemoglobin<=10% 77.7  (686) 78.4  (1345)  0.7  (-3.1 to 4.5) 0.72 Worse till 2001, improving since 
Glycated haemoglobin<=7% 13.6  (686) 12.2  (1345)  -1.3  (-4.4 to 1.8) 0.39 Worse till 2001, improving since 
Systolic blood pressure <=140mmHg 78.4  (598) 72.2  (1144)  -6.2  (-10.4 to -2.0) 0.005 Recent deterioration 
Diastolic blood pressure <=80mmHg 75.4  (598) 74.0  (1144)  -1.5  (-5.7 to 2.8) 0.51 No significant change 
Cholesterol <=5mmol/l 43.2  (236) 60.3  (1078)  17.1  (10.1 to 24.0) <0.001 Slow continuous improvement 
 
Mean glycated haemoglobin (%) 
 
8.75 
 
8.88 
  
 0.13  (0.02 to 0.24) 
 
0.008 
 
Worse till 2001, improving since 
Mean systolic blood pressure (mmHg) 129.4 132.4  3.0  (1.7 to 4.3)  <0.001 Recent deterioration 
Mean diastolic blood pressure (mmHg) 76.2 75.1  -1.1  (-1.8 to -0.4) 0.001 Slow continuous improvement 
Mean cholesterol (mmol/l) 5.28 4.85  -0.43  (-0.51 to -0.35) <0.001 Slow continuous improvement 
 
*Process measures = percentage of patients with record of process in previous 12 months; intermediate outcome measures = percentage of patients with measurement in last 12 months achieving 
target value 
# Bonferroni corrected threshold for significance p=0.003 
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Table 4: Change in quality 1st January 1998 to 1st January 2005 for people with type-2 diabetes 
Indicator* % (n) achieving 
measure 1/1/98 
% (n) achieving 
measure 1/1/05 
Difference 1998-2005 
(95% confidence interval) 
p-value# Pattern of change (see web-only 
figures 1-8) 
Glycated haemoglobin measured 58.8  (7668) 94.2  (12060) 35.4  (34.2 to 36.6) <0.001 Rapid rise before 2000 
Blood pressure measured 61.1  (7668) 87.0  (12060) 25.9  (24.6 to 27.1) <0.001 Rapid rise before 2000 
Cholesterol measured 26.5  (7668) 91.2  (12060) 64.7  (63.6 to 65.8) <0.001 Rapid rise before 2000 
Creatinine measured 41.7  (7668) 94.6  (12060) 52.9  (51.7 to 54.1) <0.001 Rapid rise before 2000 
Smoking recorded 82.9  (7668) 97.0  (12060) 14.1  (13.2 to 15.0) <0.001 Rapid rise before 2000 
Foot vascular status assessed 47.2  (7668) 74.7  (12060) 27.4  (26.1 to 28.8) <0.001 Slow continuous improvement 
Foot neurological status assessed 38.2  (7668) 73.8  (12060) 35.6  (34.3 to 36.9) <0.001 Slow continuous improvement 
Retinal screening 66.7  (7668) 75.8  (12060) 9.1  (7.8 to 10.4) <0.001 Improvement after redesign in 2003 
Glycated haemoglobin<=10% 90.4  (4511) 93.6  (11365) 3.2  (2.2 to 4.2) <0.001 Worse till 2001, improving since 
Glycated haemoglobin<=7% 42.9  (4511) 48.5  (11365) 5.7  (4.0 to 7.4) <0.001 Worse till 2001, improving since 
Systolic blood pressure <=140mmHg 50.7  (4685) 57.7  (10489) 7.0  (5.3 to 8.7) <0.001 Slow continuous improvement 
Diastolic blood pressure <=80mmHg 57.8  (4685) 68.8  (10489) 10.9  (9.3 to 12.6) <0.001 Slow continuous improvement 
Cholesterol <=5mmol/l 30.7  (2031) 72.8  (11000) 42.0  (39.9 to 44.2) <0.001 Slow continuous improvement 
 
Mean glycated haemoglobin (%) 
 
7.57 
 
7.43 
 
-0.14  (-0.18 to -0.10) 
 
<0.001 
 
Worse till 2001, improving since 
Mean systolic blood pressure (mmHg) 144.6 140.3 -4.3  (-4.8 to -3.9) <0.001 Slow continuous improvement 
Mean diastolic blood pressure (mmHg) 81.2 76.1 -5.1  (-5.3 to -4.8) <0.001 Slow continuous improvement 
Mean cholesterol (mmol/l) 5.61 4.60 -0.9  (-1.02 to -0.96) <0.001 Slow continuous improvement 
 
*Process measures = percentage of patients with record of process in previous 12 months; intermediate outcome measures = percentage of patients with measurement in last 12 months achieving 
target value 
# Bonferroni corrected threshold for significance p=0.003 
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Comparisons of quality in Tayside and elsewhere in the UK are difficult because audit is 
generally less complete in other regions. Comparisons of intermediate outcomes are 
particularly problematic because of sensitivity to case-mix variation. Additionally, the 2004 
general practice contract incentivises many of the measures presented here, although it is 
notable that quality improvement in Tayside long predates financial incentives.22 Table 5 
compares process quality in Tayside against the English National Diabetes Audit and the 
Scottish Diabetes Survey in 2004, and is consistent with TDMCN having above average 
quality in this period.  
 
Table 5: Comparison of Tayside, English National Diabetes Audit (NDA), and Scottish 
Diabetes Survey process data for adult type-1 and type-2 diabetes combined 
Process done* Tayside June 2004 
 
N=12,871 
English NDA 2004 
 
N=253,000 
Scottish Diabetes 
Survey 2004 
(Scottish mean) 
N=161,946 
Glycated haemoglobin measured 
Cholesterol measured 
Blood pressure measured 
Creatinine measured 
Retinopathy screening 
96% 
91% 
93% 
96% 
83% 
76% 
75% 
86% 
75% 
47% 
74% 
69% 
78% 
69% 
60% 
*Previous 12 months for Tayside and English NDA, previous 15 months for Scottish Diabetes Survey 
 
b) Shifting care for uncomplicated type-2 diabetes into primary care 
Rates of hospital referral for people newly diagnosed with type-2 diabetes fell dramatically 
between 2002 and 2006, with a smaller 13% fall in the proportion of patients attending the 
hospital in the previous 15 months (table 6). However, because of rising prevalence the total 
numbers of patients with type-2 diabetes being treated in hospital remained unchanged, 
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despite an additional 3191 patients being exclusively treated in primary care (a 66.2% 
increase).  
 
Table 6: Hospital attendance for people with type-2 diabetes 2002-2006 
  
2002 
 
2006 
Change in % attending 
hospital 
Hospital referral at diagnosis 
(patients newly diagnosed in 
calendar year) 
Referred 
Not referred 
 
Hospital review in 15 months 
prior to 31st Dec (all patients) 
Hospital review* 
Exclusive primary care 
 
 
 
 
 597 (47.0) 
 672 (53.0) 
 
 
 
 5665 (54.0) 
 4819 (46.0) 
 
 
 
126 (9.8) 
1162 (90.2) 
 
 
 
5615 (41.2) 
8010 (58.8) 
 
 
 
 
-37.3 (95% CI -33.8 to -40.8) 
p<0.001 
 
 
 
-12.8 (95% CI -11.6 to -14.1) 
p<0.001 
* Includes shared care with general practice 
 
Overall, there was rapid improvement in simpler processes of care, with slower and 
continuing improvements for complex processes where achievement requires more intensive 
professional education or redesign of relevant parts of the care pathway. The impact on 
intermediate outcomes is significant but smaller, particularly for people with type-1 diabetes. 
There has been a major shift to primary care for people with type-2 diabetes. However, 
because of static resources in the face of rising prevalence, hospital clinics continue to work 
at capacity which has prevented full implementation of the redesigned care pathway.  
 
Next steps  
Participants in the evaluation identified three weaknesses of the initial TDMCN model, which 
are currently being addressed by the network. First, the initial emphasis was overwhelmingly 
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on professional engagement, reflecting QI frameworks and service organisation at the time.17 
Since 2003/4, the network has actively increased patients’ involvement in network planning 
and in their own care, notably through redesign of patient education, implementing automatic 
production of individualised patient information from the web-based clinical record, and 
creating a patient portal. This reflects growing appreciation of the potential for patient and 
public involvement to improve quality of care.25 26 Second, the professionals initially engaged 
by the network were predominately clinicians, with less attention paid to NHS management. 
This proved limiting when additional resources were required to fully implement care 
pathway redesign in the face of rapidly rising prevalence. Recent more active network 
collaboration with NHS management has led to Health Board investment to facilitate fuller 
implementation of the new care pathway. Finally, type-2 diabetes care was initially 
prioritised, which is reflected in slower improvement in quality of care for people with type-1 
diabetes. Type-1 diabetes is now a network and national21 priority, although quality 
improvement will at least partly depend on the ability of the network to free specialist 
resource by shifting an even greater proportion of routine type-2 diabetes care into primary 
care. The impact of these next steps will be the subject of future evaluation.  
 
 
Wider implications 
To the best of our knowledge, this is the first systematic, independent evaluation of a 
managed clinical network anywhere in the UK where patient outcomes have been studied.17 
TDMCN implemented and sustained QI activity at all levels of the system of care. Although 
participants said that they could not easily identify which QI intervention had had the most 
impact, they did highlight the central role of information technology in supporting QI. 
 21 
However, participants were clear that IT alone did not change practice. More important was 
the way in which TDMCN successfully engaged clinicians across the region and across 
professional boundaries, persuading them to commit to improving quality of care for 
increasing numbers of people with diabetes without significant additional resources. One 
significant driver for this was the provision of a range of educational interventions, but the 
key facilitator was network leadership by enthusiastic clinicians, with a clear vision for an 
effective and equitable system of diabetes care, and a commitment to collaboration 
demonstrated by leadership being shared between specialists and general practitioners. 
Although the generalisability of networks remains uncertain, TDMCN’s experience therefore 
shows the potential of diabetes clinical networks to engage with clinicians across whole 
systems and deliver changes in professional practice and better patient care by deploying an 
appropriate range of IT-facilitated QI activities.  
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We suggest the figures be included in a web-only supplement 
Figure 1: Change in simple process measures for people with type-1 diabetes (percentage of 
patients receiving care process in previous 12 months) 
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Figure 2: Change in complex process measures for people with type-1 diabetes (percentage of 
patients receiving care process in previous 12 months) 
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Figure 3: Change in intermediate outcome targets for people with type-1 diabetes (percentage 
of patients with measurement in last 12 months who achieve target) 
0
20
40
60
80
100
Ja
n-9
8
Ap
r-9
8
Ju
l-9
8
Oc
t-9
8
Ja
n-9
9
Ap
r-9
9
Ju
l-9
9
Oc
t-9
9
Ja
n-0
0
Ap
r-0
0
Ju
l-0
0
Oc
t-0
0
Ja
n-0
1
Ap
r-0
1
Ju
l-0
1
Oc
t-0
1
Ja
n-0
2
Ap
r-0
2
Ju
l-0
2
Oc
t-0
2
Ja
n-0
3
Ap
r-0
3
Ju
l-0
3
Oc
t-0
3
Ja
n-0
4
Ap
r-0
4
Ju
l-0
4
Oc
t-0
4
Ja
n-0
5
Date
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
ac
hi
ev
in
g 
ta
rg
et
GHB <=10%
GHB<=7%
Systolic BP <=140
Diastolic BP <=80
Cholesterol <=5
 
Figure 4: Change in mean intermediate outcomes for people with type-1 diabetes (percentage 
of patients with measurement in last 12 months who achieve target) 
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Figure 5: Change in simple process measures for people with type-2 diabetes (percentage of 
patients receiving care process in previous 12 months) 
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Figure 6: Change in complex process measures for people with type-2 diabetes (percentage of 
patients receiving care process in previous 12 months) 
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Figure 7: Change in intermediate outcome targets for people with type-2 diabetes (percentage 
of patients with measurement in last 12 months who achieve target) 
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Figure 8: Change in mean intermediate outcomes for people with type-2 diabetes (percentage 
of patients with measurement in last 12 months who achieve target) 
Type 2 diabetes process measures January 1998-February 2005 (note there is both a left and right 
hand scale)
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